Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06859424 · ClinicalTrials.gov registry record · Phase 2
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
A Phase 2 study of Lymphoma and MDS (Myelodysplastic Syndrome), sponsored by Center for International Blood and Marrow Transplant Research.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 358
- Enrollment target
- 13
- Study locations
NCT06859424: Recruiting Phase 2 study of Lymphoma and MDS (Myelodysplastic Syndrome), sponsored by Center for International Blood and Marrow Transplant Research.
NCT06859424 is a Phase 2 study of Lymphoma and MDS (Myelodysplastic Syndrome) that is actively recruiting participants, run by Center for International Blood and Marrow Transplant Research. The registered enrollment target is 358 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (26% lower). The trial reports 13 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06859424, a Phase 2 study of Lymphoma and MDS (Myelodysplastic Syndrome), is actively recruiting participants, sponsored by Center for International Blood and Marrow Transplant Research.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 358 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The source of stem cells is from someone who is not related and has a different blood cell type than the study participant. The researchers will compare the new drug combination to a standard drug combination. They will also learn about the safety of each drug combination. Participants will: * Receive the standard or new drug combination after transplant * Visit the doctor's office for check-ups and tests after transplant that are routine for most transplant patients * Take surveys about physical and emotional well-being * Give blood and stool samples.
Primary Outcome
To compare GRFS following transplantation of a PBSC product from a MMUD between standard-of-care PTCy-based GVHD prophylaxis (the control arm) and the combination of reduced-dose PTCy, ruxolitinib, tacrolimus, and MMF.
Conditions Studied
Interventions
- DRUG Conditioning Regimen A
- DRUG Conditioning Regimen B
- DRUG Conditioning Regimen C
- DRUG Conditioning Regimen D
- DRUG Conditioning Regimen E
Study Locations (13)
California
- City of Hope - Duarte
- Stanford - Palo Alto
Alabama
- University of Alabama Birmingham - Birmingham
Florida
- University of Miami - Miami
Kansas
- University of Kansas Medical Center - Westwood
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- Karmanos Cancer Institute - Detroit
New York
- Memorial Sloan Kettering - New York
North Carolina
- University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 358 participants |
| Start Date | 2025-07-25 |
| Est. Completion | 2028-06 |
| Phase | Phase 2 |
What NCT06859424 shows while recruiting
NCT06859424 is an interventional study that assigns participants to a tested intervention. The registered 358 participants enrollment target is mid-sized for trials with a published cap, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (26% lower).
The record links to 10 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Conditioning Regimen A is the first listed.
NCT06859424 lists 13 locations in 12 states (California, Alabama, Florida).
Frequently Asked Questions
What is clinical trial NCT06859424 about?
NCT06859424 is a clinical study titled "A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation". The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The source of stem cells is from someone who is not related and has a different blood cell type than the s...
What is the current status of trial NCT06859424?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 358 participants. The study started on 2025-07-25. Estimated completion is 2028-06.
What conditions does trial NCT06859424 study?
This clinical trial studies the following conditions: Lymphoma, MDS (Myelodysplastic Syndrome), Chronic Myelomonocytic Leukemia (CMML), CLL (Chronic Lymphocytic Leukemia), CML (Chronic Myelogenous Leukemia).
What interventions are being tested in trial NCT06859424?
The interventions under investigation include: Conditioning Regimen A (DRUG), Conditioning Regimen B (DRUG), Conditioning Regimen C (DRUG), Conditioning Regimen D (DRUG), Conditioning Regimen E (DRUG).
Who is sponsoring clinical trial NCT06859424?
This trial is sponsored by Center for International Blood and Marrow Transplant Research, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06859424 being conducted?
This trial has 13 study locations across Alabama, California, Florida, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06859424's enrollment target sits among peer trials
358 27th of 299 higher than 273 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04373317 · 358 participants · Phase 4
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
- NCT05684965 · 358 participants · Phase 1
XTX301 in Patients With Advanced Solid Tumors
- NCT05824975 · 358 participants · Phase 1
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- NCT06480227 · 358 participants · NA
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI